The companies have kept further terms of the agreement confidential.
ZyGEM CEO Paul Kinnon said the RNA extraction technology represents an advance in sample preparation for RNA-based testing and analysis.
The reagents for quantitative PCR are used to enable applications for gene expression, pathogen detection and genetic analyses in industries such as pharmaceutical R&D, diagnostics, agribusiness and bio-defense.
ZyGEM’s enzymatic technology provides complete extraction of RNA, such as smaller RNA molecules, non-coding RNA and micro-RNA, using a single tube process.
The technology delivers higher molecular weight RNA, representative transcriptome profiles and ensures 100% reproducible results, ZyGEM said.